Abstracts tagged "rheumatoid arthritis (RA) and treatment"

Abstract Number: 2462 • 2017 ACR/ARHP Annual Meeting
Tapering TNF Inhibitors in Rheumatoid Arthritis: A Retrospective Study
Ayse Hacioglu¹, Gulen Hatemi², Sinem Nihal Esatoglu², Yesim Ozguler², Serdal Ugurlu¹, Emire Seyahi², Melike Melikoglu², Izzet Fresko², Huri Ozdogan², Sebahattin Yurdakul² and Vedat Hamuryudan², ¹Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: Current guidelines on RA treatment recommend tapering of biologic DMARDs for patients in persistent remission. Methods: In this retrospective study we used the hospital…
Abstract Number: 455 • 2017 ACR/ARHP Annual Meeting
Analysis of Real-World Treatment Patterns in a Matched Sample of Rheumatology Patients with Continuous Infliximab Therapy or Switched to Biosimilar Infliximab
Lorie A. Ellis¹, Ismail Simsek², Lin Xie³, Adesuwa Ogbomo³, Dennis Parenti⁴, Kavitha Goyal⁴ and Yusuf Yazici⁵, ¹Janssen HECOR Immunology, Horsham, PA, ²Guven Hospital, Ankara, Turkey, ³STATinMED Research Inc., Ann Arbor, MI, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, ⁵New York University School of Medicine, New York, NY
Background/Purpose: Biosimilar infliximab (CT-P13) was first approved in Europe in 2013.This study compared treatment (tx) patterns of Turkish pts with a diagnosis of rheumatoid arthritis(RA)…
Abstract Number: 2863 • 2017 ACR/ARHP Annual Meeting
Serum Proteomic Signatures Predict Relapse in Rheumatoid Arthritis Patients Undergoing DMARD Withdrawal
Liam O'Neil¹, Victor Spicer², Carol A Hitchon², Juergen Rech³, Axel J. Hueber⁴, John Wilkins², Hani El-Gabalawy¹ and Georg Schett³, ¹Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ²University of Manitoba, Winnipeg, MB, Canada, ³Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Erlangen, Germany., Erlangen, Germany, ⁴Department of Medicine 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Early and targeted treatment strategies have led to increasing numbers of patients with RA achieving sustained clinical remission. If and when to taper Disease…
Abstract Number: 2240 • 2016 ACR/ARHP Annual Meeting
A Descriptive Analysis of Real-World Treatment Patterns in a Turkish Rheumatology Population That Continued Innovator Infliximab (Remicade) Therapy or Switched to Biosimilar Infliximab
Yusuf Yazici¹, Lin Xie², Adesuwa Ogbomo³, Dennis Parenti⁴, Kavitha Goyal⁴, Amanda Teeple⁴, Lorie A. Ellis⁵ and Ismail Simsek⁶, ¹New York University, Hospital of Joint Diseases, New York, NY, ²Director, Health Economics & Outcomes Research, STATinMED Research, Ann Arbor, MI, ³STATinMED Research Inc., Ann Arbor, MI, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, ⁵Health Economics & Outcomes Research, Janssen Scientific Affairs, LLC, Horsham, PA, ⁶Guven Hospital, Ankara, Turkey
Background/Purpose: This study examined treatment patterns in a rheumatology patient (pt) population initially prescribed innovator infliximab (IFX) that either switched to biosimilar infliximab (CT-P13) or…
Abstract Number: 2479 • 2016 ACR/ARHP Annual Meeting
Work Productivity in Early Rheumatoid Arthritis Patients Treated before and after Implementation of a Treat-to-Target Strategy
Siri Lillegraven¹, Maria Dahl Mjaavatten¹, Nina P. Sundlisater¹, Anna-Birgitte Aga¹, Inge C Olsen², Till Uhlig¹, Daniel H. Solomon³, Tore K Kvien¹, Espen A. Haavardsholm¹ and the ARCTIC Study Group, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Division of Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) is a known cause of work productivity loss. Participation in work-related activities is defined as part of the primary goal of…
Abstract Number: 2494 • 2016 ACR/ARHP Annual Meeting
The Effect of Body Mass on DAS28 Response in Patients with Rheumatoid Arthritis Treated with Abatacept
J Fransen¹, L Tweehuysen², A den Broeder³, R Postema⁴, E Alemao⁵ and F van den Hoogen⁶, ¹Department of Rheumatolgy, Radboud UMC, Nijmegen, Netherlands, ²Sint Maartenskliniek Nijmegen, Nijmegen, Netherlands, ³Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ⁴Bristol-Myers Squibb, Uxbridge, United Kingdom, ⁵Bristol-Myers Squibb, Princeton, NJ, ⁶Rheumatology, Radboud UMC, Nijmegen, Netherlands
Background/Purpose: Abatacept is an effective biologic agent indicated for the treatment of RA.1 Recent studies have indicated that obesity and being overweight could reduce the…
Abstract Number: 2536 • 2016 ACR/ARHP Annual Meeting
The Performance of a Single Centre Interventional Clinic in Early Rheumatoid Arthritis
Rok Jese¹, Ales Ambrozic², Natasa Gaspersic², Alojzija Hocevar¹, Boris Lestan¹, Milena Pavic Nikolic¹, Martina Plešivčnik Novljan², Sonja Praprotnik³, Ziga Rotar¹, Alenka Šipek Dolničar¹, Dasa Suput Skvarca¹ and Matija Tomsic¹, ¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ²Department of Rheumatology, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia, ³Department of Rheumatology, University Medical Centre Ljubljana, Slovenia, Ljubljana, Slovenia
Background/Purpose: In early rheumatoid arthritis (RA), first assessment by a rheumatologist and/or initiation of disease-modifying anti-rheumatic drugs (DMARD) within 12 weeks of symptom onset are…
Abstract Number: 2635 • 2016 ACR/ARHP Annual Meeting
Using Patient Reported Outcomes to Inform a Treat to Target Treatment Approach in RA
Eric M. Ruderman¹, Jennifer Beaumont², Emily Bacalao¹, George J. Greene², Azra Muftic² and David Cella², ¹Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: The Patient Reported Outcomes Measurement Information System (PROMIS) is an NIH initiative to develop patient-reported outcome measures (PROs) for use across chronic conditions. PROMIS…
Abstract Number: 2636 • 2016 ACR/ARHP Annual Meeting
No Strong Evidence Supporting Predictors for Successful Dose Reduction or Discontinuation of a Biologic in Rheumatoid Arthritis: A Systematic Review
L. Tweehuysen¹, C.H. van den Ende², F.M.M. Beeren², E.M.J. Been², F.H.J. van den Hoogen^3,4 and A.A. den Broeder³, ¹Sint Maartenskliniek, Nijmegen, Netherlands, ²Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ³Department of Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ⁴Rheumatology, Radboudumc, Nijmegen, Netherlands
Background/Purpose: Tapering of biologics in rheumatoid arthritis (RA) is based on a trial-and-error disease activity guided strategy, because it is not known in advance which…
Abstract Number: 2649 • 2016 ACR/ARHP Annual Meeting
Patient Preferences Regarding Rheumatoid Arthritis Therapies in Lebanon: Results from a National, Multicenter, Cross-Sectional Survey
Fouad Fayad¹, Nelly Ziade², Georges Merheb^3,4, Said Attoui⁵, Alla Aiko⁶, Kamel Mroue⁵ and Abdel Fattah Masri⁷, ¹Hotel Dieu de France Hospital and Saint Joseph University, Beirut, Lebanon, ²Rheumatology, Hotel Dieu de France Hospital and Saint Joseph University, Beirut, Lebanon, ³Internal Medicine, Notre Dame des Secours University Hospital, Jbeil, Lebanon, ⁴Holly Spirit University, Kaslik, Lebanon, ⁵Hammoud University Medical Center, Saida, Lebanon, ⁶Saint Georges Hospital, Beirut, Lebanon, ⁷American University of Beirut Medical Center, Beirut, Lebanon
Background/Purpose: Treatment options in rheumatoid arthritis (RA) have expanded significantly over recent years, and several agents are now available for oral, subcutaneous (SC) or intravenous…
Abstract Number: 607 • 2016 ACR/ARHP Annual Meeting
The Clinical Response to Biologic and Non-Biologic Disease Modifying Antirheumatic Drugs (DMARDs) According to Gender in a French-Canadian Population with Rheumatoid Arthritis (RA)
Sonia Lagacé¹, Louis Bessette^2,3, Louis Coupal⁴ and Denis Choquette⁴, ¹Medicine, Laval University, Quebec, QC, Canada, ²Rheumatology, Laval University, Québec, QC, Canada, ³Rhumatologie, CHU de Québec - Université Laval, Quebec, QC, Canada, ⁴Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada
Background/Purpose: Several studies have reported that women with RA had higher level of pain, disease activity and functional impairment compared to men. In addition, women…
Abstract Number: 2653 • 2016 ACR/ARHP Annual Meeting
Results of a Comprehensive Review of Pulmonary Function and Safety Data in a Phase IIb Clinical Program Testing Anti-GM-CSF Receptor Antagonist Mavrilimumab for Treatment of RA
GR Burmester¹, MA Michaels², D Close³, A Godwood³, K Middleton³, P Miranda⁴, J Vencovský⁵, JM Kremer⁶, IB McInnes⁷, M Albulescu^³ and Michael Weinblatt⁸, ¹Charité – University Medicine Berlin, Berlin, Germany, ²MedImmune, Gaithersburg, MD, ³MedImmune, Cambridge, United Kingdom, ⁴Centro De Estudios Reumatológicos, Santiago, Chile, ⁵Charles University, Prague, Czech Republic, ⁶The Albany Medical College, Albany, NY, ⁷University of Glasgow, Glasgow, United Kingdom, ⁸Brigham and Women’s Hospital, Boston, MA
Background/Purpose: RA is associated with significant pulmonary comorbidity and declines in lung function over time; but longitudinal assessment of pulmonary abnormalities in the context of…
Abstract Number: 610 • 2016 ACR/ARHP Annual Meeting
A Systematic Review and Meta-Analysis of Comparative Efficacy of Biologics in Treating Patients with Rheumatoid Arthritis: Assessment of Long-Term Radiographic Progression from Published Clinical Trials
Erin Murray¹, Yekaterina Butylkova¹, Alexandra Ellis¹, Martha Skup², Jasmina Kalabic³ and Vishvas Garg⁴, ¹Doctor Evidence, Santa Monica, CA, ²AbbVie Inc., North Chicago, IL, ³AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁴AbbVie Inc, North Chicago, IL
Background/Purpose: Previously, several studies have meta-analyzed clinical, functional or structural efficacy of biologics in treating rheumatoid arthritis (RA) patients. However, the comparative efficacy of biologics…
Abstract Number: 3094 • 2016 ACR/ARHP Annual Meeting
Factors Associated with Initial or Subsequent Choice of Biologic Disease Modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis
Yinzhu Jin¹, Rishi J. Desai¹, Jun Liu¹, Nam-Kyong Choi¹ and Seoyoung Kim^2,3, ¹Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, ²Division of Pharmacoepidemiology and Pharmocoeconomics, Brigham and Women's Hospital, Boston, MA, ³Brigham and Women’s Hospita and, Harvard Medical School,, Boston, MA
Background/Purpose: Treatment with disease-modifying antirheumatic drugs (DMARDs) is considered the standard of care for rheumatoid arthritis (RA). Over the past two decades, major advances have…
Abstract Number: 637 • 2016 ACR/ARHP Annual Meeting
Biologic Initiation Patterns Among Rheumatoid Arthritis Patients in Moderate or High Disease Activity While Using Conventional Disease Modifying Anti-Rheumatic Drugs
Natalie Boytsov¹, George W. Reed², Leslie R Harrold^2,3, Xiang Zhang¹, Carol L Gaich¹, Cynthia J Larmore¹, Ying Shan², S Rebello⁴ and Andre B. Araujo¹, ¹Eli Lilly and Company, Indianapolis, IN, ²Corrona, LLC, Southborough, MA, ³UMass Medical School, Worcester, MA, ⁴Epidemiology, Corrona, Southborough, MA
Background/Purpose: The purpose of this study was to describe biologic initiation patterns over a 1-year follow-up period in rheumatoid arthritis (RA) patients with moderate…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].